ClinicalTrials.gg
CompletedNCT04908787Updated Sep 11, 2025

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

A Phase 3 interventional study of BD0801 and Paclitaxel in Ovarian Cancer, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Completed at 55 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
421
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 392 studies in Ovarian Neoplasms with a site in China — 198 open to participants now, 231 under way, 35 of them phase 3. Ovarian Neoplasms · China.

Enrollment
39th of 319
421 · median 83
Started
2021
with 43 others
Phase 3
52 of 392
19 open now
Registered
130th of 392
by date

Among the 392 studies in Ovarian Neoplasms with a site in China, this one is the 39th largest by enrollment of the 319 interventional ones that give a count, is one of 44 that started in 2021, is one of 52 in phase 3, and was the 130th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

198 of the 392 studies in Ovarian Neoplasms with a site in China are open now. Recruiting first, the newest first:

193 more — sign in →

All 198 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 392 studies in Ovarian Neoplasms with a site in China, or all of them as a file.
02

Study summary

The standard systemic treatment for ovarian cancer is platinum-based chemotherapy. However, majority of patients relapse and eventually progress to platinum resistance. In patients with platinum-resistant or refractory ovarian cancer, effective treatment options are limited and the prognosis is very poor. Angiogenesis is essential for tumor growth and metastasis, and VEGF/VEGF receptor(VEGFR) signaling pathway is the most promising angiogenic target. This study aim to assess the efficacy and safety of the combination BD0801 and chemotherapy in patients with platinum-resistant recurrent ovarian cancer.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female patients, >/=18 years of age;
  • epithelial ovarian, fallopian tube or primary peritoneal cancer;
  • platinum-resistant disease (disease progression within \<6 months of platinum therapy)
  • (ECOG)performance status of 0-1

Exclusion criteria

Exclusion Criteria:

  • non-epithelial tumours
  • ovarian tumours with low malignant potential
  • Received 1 for ovarian cancer following platinum resistance and/or > 1 line of non-platinum systemic therapy prior to platinum resistance.
  • prior radiotherapy to the pelvis or abdomen
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
421 participants (actual)

Study arms

  • Experimental
    BD0801+chemotherapy

    BD0801 is in combination with one of three chemotherapies: Paclitaxel, Topotecan or Doxorubicin liposomes.

    Drug: BD0801 · Drug: Paclitaxel · Drug: Topotecan · Drug: doxorubicin liposome

  • Placebo comparator
    Placebo+chemotherapy

    Placebo is in combination with one of three chemotherapies: Paclitaxel, Topotecan or Doxorubicin liposomes.

    Drug: Paclitaxel · Drug: Placebo · Drug: Topotecan · Drug: doxorubicin liposome

Interventions

  • DrugBD0801

    Subjects receive BD0801 , intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg

  • Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, d22, q4w, Dosage form: injectable, Strength: 80 mg/m2

  • DrugPlacebo

    Subjects receive Placebo, intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg

  • Subjects receive Topotecan, intravenously, d1, d8, d15, q4w, Dosage form: injectable, Strength: 4mg/m2

  • Drugdoxorubicin liposome

    Subjects receive doxorubicin liposome, intravenously, d1, , q4w, Dosage form: injectable, Strength: 40mg/m2

06

What researchers measure

Primary outcomes

  1. Progression free survival(PFS) by blinded independent review committee(BIRC)

    PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the IRC according to the RECIST 1.1 criteria

    Time frame: 2 year

Secondary outcomes

  1. Overall Survival (OS)

    OS is the time interval from the date of randomization to death from any cause.

    Time frame: 2.5 year

  2. PFS by investigator

    PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigator according to the RECIST1.1 criteria

    Time frame: 2 year

  3. Objective Response Rate (ORR) by investigator

    Proportion of subjects who have a complete or partial response relative to baseline as assessed by investigator according to RECIST 1.1 criteria

    Time frame: 2 year

  4. Disease Control Rate (DCR) by investigator

    Proportion of subjects who have a complete or partial response, or stable disease relative to baseline as assessed by investigator according to RECIST 1.1 criteria

    Time frame: 2 year

  5. Objective Response Rate (DOR) by investigator

    Measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria.

    Time frame: 2 year

  6. ORR by BIRC

    Proportion of subjects who have a complete or partial response relative to baseline as assessed by BIRC according to RECIST 1.1 criteria

    Time frame: 2 year

  7. DCR by BIRC

    Proportion of subjects who have a complete or partial response, or stable disease relative to baseline as assessed by BIRC according to RECIST 1.1 criteria

    Time frame: 2 year

  8. DOR by BIRC

    Measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria.

    Time frame: 2 year

  9. The incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    Frequency and severity of Adverse Events or Serious Adverse Events as defined by CTCAE version 5.0

    Time frame: 2.5 year

  10. Quality Of Life (QoL)

    use European Organisation for Research and Treatment of Cance(EORTC)- QLQ-C30 questionnaire

    Time frame: 2.5 year

  11. Quality Of Life (QoL)

    use EORTC-QLQ-OV28 questionnaire

    Time frame: 2.5 year

  12. Serum drug concentrations of BD0801

    Serum drug concentrations of BD0801 will be calculated.

    Time frame: 2 year

  13. rate of immunogenicity positive reaction

    Time frame: 2 year

  14. duration of immunogenicity positive reaction

    Time frame: 2 year

07

Study locations

55 sites
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, Anhui, China
  • The First Affiliated Hospital of USTC West District,Anhui Provincial Cancer Hospital
    Hefei, Anhui, China
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui, China
  • Beijing Obstetrics and Gynecology Hospital, Capital Medical University
    Beijing, Beijing Municipality, China
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality, China
  • Peking University First Hospital
    Beijing, Beijing Municipality, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing Municipality, China
  • Fujian Provincial Cancer Hospital
    Fuzhou, Fujian, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong, China
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong, China
  • Cancer Hospital Chinese Academy Of Medical Sciences, Shenzhen Center
    Shenzhen, Guangdong, China
  • Guangxi Medical University Cancer Hospital&Guangxi Cancer Institute, Guangxi Cancer Hospital&Medical University School&Cancer Center
    Nanning, Guangxi, China
  • Guizhou Provincial People's Hospital
    Guiyang, Guizhou, China
  • Hainan General Hospital
    Haikou, Hainan, China
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang, China
  • The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
    Zhengzhou, Henan, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • Hubei Cancer Hospital
    Wuhan, Hubei, China
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The First Affiliated Hospital of University of South China
    Hengyang, Hunan, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu, China
  • Nanjing Women and Children's Healthcare Hospital, Women's Hospital of Nanjing Medical University
    Nanjing, Jiangsu, China
  • Nantong Cancer Hospital
    Nantong, Jiangsu, China
  • Xuzhou Central Hospital(Southeast University Affiliated Hospital)
    Xuzhou, Jiangsu, China
  • Jiangxi Maternal and Child Health Hospital
    Nanchang, Jiangxi, China
  • Jilin Cancer Hospital
    Changchun, Jilin, China
  • The First Hospital of Jilin University
    Changchun, Jilin, China
  • The Second Norman Bethune Hospital of Jilin University
    Changchun, Jilin, China
  • The Second Hospital of Dalian Medical University
    Dalian, Liaoning, China
  • Fukuang General Hospital of Liaoning Health Industry Group
    Fushun, Liaoning, China
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
  • Shandong Cancer Hospital & Institute
    Jinan, Shandong, China
  • Affiliated Hospital of Jining Medical University
    Jining, Shandong, China
  • Linyi Cancer Hospital
    Linyi, Shandong, China
  • Yantai Yuhuangding Hospital
    Yantai, Shandong, China
  • Obstetrics & Gynecology Hospital of Fudan University
    Shanghai, Shanghai Municipality, China
  • Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • Mianyang Central Hospital
    Mianyang, Sichuan, China
  • Affiliated Hospital of North Sichuan Medical College
    Nanchong, Sichuan, China
  • Tianjin Center Hospital of Gynecology Obstetrics
    Tianjin, Tianjin Municipality, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin Municipality, China
  • Hangzhou Cancer Hospital
    Hangzhou, Zhejiang, China
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Dec 2023, 29 months.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 29 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2021
First posted
Jun 1, 2021
StartActual
Jun 11, 2021
Primary completionActual
Dec 8, 2023
CompletionActual
Oct 11, 2024
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04908787
Collaborators
Shanghai Xianxiang Medical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Jun 1, 2021
Start date
Jun 11, 2021
Primary completion
Dec 8, 2023
Completion
Oct 11, 2024
Last update
Sep 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suvemcitug

Start the discussion